{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:54:47Z","timestamp":1696334087469},"reference-count":20,"publisher":"Japan Atherosclerosis Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2003]]},"DOI":"10.5551\/jat.10.19","type":"journal-article","created":{"date-parts":[[2011,6,16]],"date-time":"2011-06-16T13:45:32Z","timestamp":1308231932000},"page":"19-24","source":"Crossref","is-referenced-by-count":1,"title":["Related Factors of Meeting National Cholesterol Education Program-recommended Goals with Atorvastatin"],"prefix":"10.5551","volume":"10","author":[{"given":"Yuji","family":"Yoshitomi","sequence":"first","affiliation":[{"name":"Miyauchi Makoto Memorial Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Tsujibayashi","sequence":"additional","affiliation":[{"name":"Tsujibayashi Medical Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Ishii","sequence":"additional","affiliation":[{"name":"Ishii Medical Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-ichiro","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Sakurai Medical Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieko","family":"Nagakura","sequence":"additional","affiliation":[{"name":"Miyauchi Makoto Memorial Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuyoshi","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Miyauchi Makoto Memorial Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"(1) Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S).  Lancet, 344: 1383-1389, 1994","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"(2) Holmes I: An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence.  Circulation, 82: 1916-1924, 1990","DOI":"10.1161\/01.CIR.82.6.1916"},{"key":"3","doi-asserted-by":"crossref","unstructured":"(3) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults.  Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II).  JAMA, 269: 3015-3024, 1993","DOI":"10.1001\/jama.1993.03500230097036"},{"key":"4","unstructured":"(4) Davignon J, Montigny M, and Dufour R: HMG-CoA reductase inhibitors: a look back and a look ahead.  Can J Cardiol, 8: 843-864, 1992"},{"key":"5","doi-asserted-by":"crossref","unstructured":"(5) Shephed J: Statins. Is there a need for alternative or adjunctive therapy?  Br Heart J, 74: 13, 1995","DOI":"10.1136\/hrt.74.1.13"},{"key":"6","doi-asserted-by":"crossref","unstructured":"(6) Rubenfire M, Maciejko JJ, Blevins RD, Orringer C, Kobylak L, Rosman H, and Southeastern Michigan Collaborative Group: The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia.  Arch Intern Med, 151: 2234-2240, 1991","DOI":"10.1001\/archinte.151.11.2234"},{"key":"7","doi-asserted-by":"crossref","unstructured":"(7) Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, and Black DM: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.  Arterioscler  Thromb Vasc Biol, 15: 678-682, 1995","DOI":"10.1161\/01.ATV.15.5.678"},{"key":"8","doi-asserted-by":"crossref","unstructured":"(8) Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, and Black D: Comparison on one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia: Atorvastatin Study Group I.  Am J Cardiol, 79: 1475-1481, 1997","DOI":"10.1016\/S0002-9149(97)00174-4"},{"key":"9","unstructured":"(9) Garrow JS: Obesity. In: Oxford Textbook of Medicine. 3rd Ed, ed by Ledingham JGG, Weatherall DJ, Warrell DA, pp 1301-1314, Oxford Medical Publications, Oxford, New York, 1999"},{"key":"10","doi-asserted-by":"crossref","unstructured":"(10) Freidewald WT, Levy RI, and Fredrikson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of a centrifuge.  Clin Chem, 18: 449-502, 1972","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"11","doi-asserted-by":"crossref","unstructured":"(11) Hotamisligil GS, Arner P, Caro JF, Atkinson RL, and Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.  J Clin Invest, 95: 2409-2415, 1995","DOI":"10.1172\/JCI117936"},{"key":"12","doi-asserted-by":"crossref","unstructured":"(12) Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, and Goldstein JL: Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob\/ob mice.  Mol Cell, 6: 77-86, 2000","DOI":"10.1016\/S1097-2765(05)00010-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"(13) Schreibman PH and Dell RB: Human adipocyte cholesterol.  Concentration, localization, synthesis, and turnover.  J Clin Invest, 55: 986-993, 1975","DOI":"10.1172\/JCI108028"},{"key":"14","unstructured":"(14) Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP. Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Menp, Mlknen M, Mnttri M, Norola S,  Pasternack A, Pikkarainen J, Sjblom T, and Nikkil EA: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.  JAMA, 260:641-651, 1988"},{"key":"15","doi-asserted-by":"crossref","unstructured":"(15) Hsu I, Spinler SA, and Johnson NE: Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.  Ann Pharmacother, 29:743-759, 1995","DOI":"10.1177\/106002809502907-818"},{"key":"16","doi-asserted-by":"crossref","unstructured":"(16) Shepherd J: Fibrates and statins in the treatment of hyperlipidemia: an appraisal of their efficacy and safety.  Eur Heart J, 16:5-13, 1995","DOI":"10.1093\/eurheartj\/16.1.5"},{"key":"17","doi-asserted-by":"crossref","unstructured":"(17) Smilde TJ, Wissen van S, Wollersheim H, Trip MD, Kastelein JJP, and Stalenhoef AFH: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial.  Lancet, 357: 577-581, 2001","DOI":"10.1016\/S0140-6736(00)04053-8"},{"key":"18","unstructured":"(18) Hunninghake D, Bakker-Arkema RG, Wigand JP, Drehobl M, Schrott H, Early JL, Abdallah P, McBride S, and Black DM: Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.  J Fam Pract, 47: 349-356, 1998"},{"key":"19","doi-asserted-by":"crossref","unstructured":"(19) Brown AS, Bakker-Arkema RG, Yellen L, Henley RW, Guthrie R, Campbell CF, Koren M, Woo W, McLain R, and Black DM: Treating patients with documented atherosclerosis to National Cholesterol Education Program-Recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.  J Am Coll Cardiol, 32: 665-672, 1998","DOI":"10.1016\/S0735-1097(98)00300-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"(20) Black DM, Bakker-Arkema RG, and Nawrocki JW: An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor.  Arch Inter Med, 158: 577-584, 1998","DOI":"10.1001\/archinte.158.6.577"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/10\/1\/10_1_19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T02:19:31Z","timestamp":1623377971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/10\/1\/10_1_19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.10.19","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003]]}}}